QHP is seeking to support the scientific leadership of ASC with commercial and operational expertise to help the Company capture share in a fast-growing segment of regenerative medicine.

QHP partnered with AutoCruitment to scale clinical trial recruitment using digital platforms and workflows.

QHP partnered with founder-owned Elusa Health to help at an inflection point as they work to quickly connect more patients to complex treatments.

Since 2018, QHP Capital has invested over $1 billion across 10 platform companies in life science and pharma services.

MAITLAND, FL. March 17, 2026. COPILOT Provider Services today announced its official rebrand as Elusa Health, marking a significant evolution in the company’s identity and its commitment to transforming how patients access therapies in an increasingly complex healthcare system.

Dr. David Almeida joins Lexitas as Chief Retina Strategy Officer as the company builds a unified, science-first ecosystem for complex vitreoretinal studies.

The transaction provides liquidity option to existing investors and secures long-term capital to support continued growth.

Adrian is responsible for transaction execution, industry research and analysis, and portfolio oversight.

Ed Seguine has over 25 years of experience in biotech and pharma technology, founding and leading companies through growth stages, including Clinical Ink.

Richard is responsible for leading fund operations, financial reporting, treasury, and valuation.

Russ is responsible for driving value creation and operational excellence at QHP portfolio companies, with a specific focus on Azurity.

QHP Capital invests in middle-market healthcare companies, focusing on tech-enabled life sciences and pharma services that improve patient care and efficiency.

The company collaborates with management teams to build long-term value in life science and pharma services businesses.

QHP Capital protects user privacy through compliance with its privacy policy.